Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD1208||AZD-1208||PIM Inhibitor (Pan) 9||AZD1208 is a pan-PIM kinase inhibitor, which blocks PIM downstream signaling and leads to cell cycle arrest and apoptosis (PMID: 25505253, PMID: 32344898).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK2 V617F||bone marrow cancer||decreased response||AZD1208||Preclinical||Actionable||In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to AZD1208 induced growth inhibition in culture (PMID: 26472029).||26472029|
|Unknown unknown||Advanced Solid Tumor||not applicable||AZD1208||Phase I||Actionable||In a Phase I trial, AZD1208 treatment was tolerated and demonstrated activity in pharmacodynamic studies, resulted in stable disease for 6 weeks or longer as best objective response in 48% (13/27) of evaluable patients with advanced solid tumor (PMID: 29765150; NCT01588548).||29765150|
|Unknown unknown||prostate cancer||not applicable||AZD1208||Preclinical - Cell line xenograft||Actionable||In a preclinical study, AZD1208 inhibited tumor growth in castrate-resistant prostate cancer cell line xenograft models (PMID: 25505253).||25505253|
|Unknown unknown||prostate cancer||not applicable||AZD1208||Case Reports/Case Series||Actionable||In a Phase I trial, AZD1208 treatment resulted in considerable decrease of PSA levels in a patient with prostate cancer (PMID: 29765150; NCT01588548).||29765150|
|Unknown unknown||acute myeloid leukemia||no benefit||AZD1208||Phase I||Actionable||In a Phase I trial, AZD1208 treatment was tolerated and demonstrated activity in pharmacodynamic studies, but resulted in no clinical response (0/32) in patients with acute myeloid leukemia (PMID: 29765150; NCT01489722).||29765150|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|